title: Reduction in requirements for allogeneic blood products: pharmacologic methods.
abstract: BACKGROUND
  Numerous articles describe the reduction of perioperative bleeding by the therapeutic or prophylactic administration of drugs such as prostacyclin, desmopressin, and natural or synthetic antifibrinolytics.
  
  
  METHODS
  A review of the literature was carried out to help the reader define the indications of these drugs during cardiopulmonary bypass operations, highlight the questions that remain concerning their indications and modes of action, and suggest future studies to answer these remaining questions.
  
  
  RESULTS
  Prostacyclin reduces platelet trauma induced by extracorporeal circulation but does not effectively reduce postoperative bleeding and transfusion requirements. Desmopressin acts as a "glue," improving platelet adhesion, and may be effective when postoperative bleeding is excessive, but its routine use in cardiac operations cannot be recommended. Natural and synthetic antifibrinolytics inhibit plasmin and plasmin-induced platelet dysfunction. These agents have been shown to decrease bleeding and the need for allogeneic transfusions after open heart operations. However, with antifibrinolytic drugs, the risk of thromboembolic phenomena cannot be neglected. With aprotinin, this risk appears to be minimal when the drug is used at concentrations high enough to inhibit plasma kallikrein also.
  
  
  CONCLUSIONS
  Prophylactic antifibrinolytics are efficacious, but their routine use remains controversial, both for economic reasons and for fear of thromboembolic complications.
authors.affiliation: Department of Anesthesia and Intensive Care Medicine, University Hospital of Liège, Belgium.
authors.forename: M
authors.initials: M
authors.lastname: Janssens
authors.forename: G
authors.initials: G
authors.lastname: Hartstein
authors.forename: J L
authors.initials: JL
authors.lastname: David
mesh_terms: D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D007611:Aprotinin / Q000627:therapeutic use; D001803:Blood Transfusion; D006348:Cardiac Surgical Procedures; D002315:Cardiopulmonary Bypass; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use*; D011464:Epoprostenol / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006488:Hemostasis, Surgical; D006801:Humans; D019106:Postoperative Hemorrhage / Q000188:drug therapy* / Q000517:prevention & control / Q000628:therapy
chemical_list: D000933:Antifibrinolytic Agents; D007611:Aprotinin; D011464:Epoprostenol; D003894:Deamino Arginine Vasopressin